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We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chron-ic lymphocytic leukemia (CLL). In an intention-to-treat analy-
sis including 237 patients, the median progression-free survival (PFS) was
25 months. The presence of del(17p), unmutated IGHV and advanced
stage were associated with a shorter PFS at multivariate analysis. The
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ABSTRACT
Introduction
Treatment of chronic lymphocytic leukemia (CLL) has
dramatically changed over the last years. Chemotherapy
and anti-CD20 monoclonal antibodies produce high over-
all response rates (ORR), including complete remissions
(CR) with negative minimal residual disease, and pro-
longed progression-free-survival (PFS) and overall survival
(OS), both in fit1,2 and unfit patients.3 In patients with TP53
disruption and/or with relapsed/refractory (R/R) disease,
who represent a difficult-to-treat patient population,
mechanism-driven drugs targeting the Bruton tyrosine
kinase (BTK), the phosphoinositide 3-kinase delta (PI3K δ)
or the BCL2 protein can induce durable responses.4-7
In the absence of TP53 disruption, a chemoim-
munotherapy (CIT) regimen is recommended as front-line
and  second-line treatment in those patients who attained
a long progression-free survival (PFS) with the previous
regimen.8,9 On the other hand, the National
Comprehensive Cancer Network recommends one of the
new agents, ibrutinib, idelalisib with rituximab or veneto-
clax, as alternatives to CIT for patients with relapsed or
refractory disease.10
Uncertainty in the recommendations on first salvage
treatment may partly derive from the consideration that
the majority of studies on R/R CLL report efficacy data in
an aggregate fashion, analyzing patients who had previ-
ously received one or more lines of treatment all together.
Consequently, little information is currently available on
the outcome of second-line treatment.
Bendamustine and rituximab (BR) is one of the most
widely adopted CIT regimens, both as front-line11 and sec-
ond-line treatment.12-14 The BR regimen was followed by a
median PFS of  18 months when used as first salvage treat-
ment after fludarabine, cyclophosphamide and rituximab
(FCR) in 62 patients regardless of TP53 aberrations and/or
refractoriness to prior therapy.13 In 78 CLL patients who
had received 1-3 previous lines of treatment, the BR com-
bination was associated with a 59% ORR with a median
PFS of 15.2-months.15 Bendamustine and ofatumumab
produced a 23.6-month median PFS in 47 patients, 61%
and 29% of whom had received 1 or 2 prior lines of treat-
ment, respectively.16
The oral agent ibrutinib represents an effective therapy
in the R/R setting.17 In a recent analysis describing a 5-year
experience, a median PFS of 52 months was reported in
R/R CLL treated with ibrutinib after 4 or more previous
lines of treatment in more than 50% of patients.18 In a
recent update of the phase III Resonate study comparing
ibrutinib and ofatumumab, the PFS rate appeared to be
better in patients treated with ibrutinib in second line
compared to patients who had received 2 or more previ-
ous lines of treatment.19
Recent experiences with ibrutinib in a real-world setting
have reported a higher rate of discontinuation compared
to clinical trials,20,21 possibly due to older age and worse
Performance Status (PS) of the patient population treated
in the day-to-day clinical practice.22
On these grounds, we performed a retrospective obser-
vational study within the Gruppo Italiano Malattie
Ematologiche dell'Adulto (GIMEMA) and European
Research Initiative on CLL (ERIC) networks to collect data
on the efficacy and safety profile of the BR regimen used
as second-line treatment in a real-world setting. We then
set out to perform an indirect comparison with ibrutinib
given as first salvage treatment in the UK and the Italian
Named Patient Programs (NPP). 
Methods 
Patients 
Patients treated between 2008 and 2014 at GIMEMA and ERIC
centers were eligible. The inclusion criteria were: i) diagnosis of
CLL according to the National Cancer Institute (NCI);23 ii) age ≥18
years; iii) one previous treatment using alkylating agents and/or
purine analogs with or without monoclonal antibodies; iv) pro-
gression requiring therapy (NCI criteria);23 v) second-line treat-
ment with BR at the conventional dose of 70 mg/m2, as
described.15
Patients were excluded if they had Richter’s syndrome transfor-
mation, HIV infection, active HCV or HBV infection. The study
was registered at clinicaltrials.gov identifier: 02491398. The study
was approved by the local ethics committees.
Study design and end points
Data were obtained from the medical files and entered into case
record forms (CRF) by treating physicians. Computerized and
manual consistency checks were performed by the data manager
of the GIMEMA data center. 
Evaluation of bone marrow response and radiographic imaging
at baseline and at response were performed according to local
guidelines. Treatment response and disease progression were
assessed according to the NCI criteria.23
Primary end point
The primary end point was PFS at 12 months from treatment
start. Subjects who were withdrawn from the study without pro-
gression were censored at the date of the last assessment. Subjects
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median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy
regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The
median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage
C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5
infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib
given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out
with OS as objective end point. When restricting the analysis to patients with intact 17p who had
received chemoimmunotherapy in first line, there was no difference in OS between patients treated with
ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an effi-
cacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR
and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients
without 17p deletion.  (Registered at clinicaltrials.gov identifier: 02491398)
without post-baseline assessments but known to be alive were
censored at the time of first dose of study drug.
Secondary end points 
The ORR was assessed in all the patients who started treatment
(intention to treat). Time to next anti-leukemic treatment (TTNT)
was calculated using the cumulative incidence method, from the
date of the first dose of the study drugs until the date of retreat-
ment. OS was calculated from the date of the first dose of the
study drug until the date of death. Patients without follow-up
assessment were censored at the day of the last treatment admin-
istration. Evaluation of safety was reported according to NCI
Common Terminology Criteria for Adverse Events version 4.0.
Indirect comparison with ibrutinib 
Data from patients treated in second line with single agent ibru-
tinib in the UK and Italy within the NPP were retrospectively
retrieved. Patients with R/R CLL treated in the UK have been
reported previously.20 Patients treated in Italy were extracted from
the GIMEMA LLC1415 trial (clinicaltrials.gov identifier: 02582320).
The end point for this analysis was OS.
Statistical analysis
Statistical analysis was performed following the intention-to-
treat principle. Non-parametric tests were applied for comparisons
between groups (χ2 and Fisher Exact test for categorical variables
or response rate, Mann-Whitney and Kruskal-Wallis test for con-
tinuous variables) and logistic regression were applied in multi-
variate analysis.  Survival distributions were estimated using the
Kaplan-Meier Product Limit estimator.
Differences in terms of PFS, TTNT and OS were evaluated by
Log-Rank test in univariate analysis and Cox regression model in
multivariate analysis.
Cumulative Incidence curves were estimated using the proper
non-parametric method. The Gray test was applied for signifi-
cance tests on cumulative incidence curves.
All the analyses were performed using the SAS software (v.9.4
or later); all tests were two-sided. P=0.05 was considered statisti-
cally significant. Confidence intervals were calculated at 95%
(95%CI).
Results
Patients’ characteristics 
A total of 237 patients treated at 37 centers (28 centers
belonging to the GIMEMA group and 9 centers affiliated
with the ERIC group) were enrolled (Online Supplementary
Table S1). Baseline patients’ characteristics are outlined in
Table 1: median age was 70.4 years, range 39.4-87.8;
70.9% of patients were over 65 years old; 58.3% had 2 or
more comorbidities; 46.9% had a creatinine clearance ≤70
ml/min; and 21.4% had an advanced disease stage (i.e. Rai
III-IV or Binet C). Seventy-three percent (data available in
61.6% of the patients) had an unmutated tumor
immunoglobulin gene heavy chain variable region config-
uration (U-IGHV) and 33.4% had 11q- and/or 17p13 dele-
tion (data available in 79.3% of the patients). These
patients were representative of the entire study popula-
tion in terms of baseline characteristics and outcome (data
not shown). 
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Table 1. Patients' characteristics.
Frequency (%)
Variable Benda + R Ibrutinib P
n=237 n=95
Age, years [median, range] 70.4 [39.4-87.8] 69.3 [27.5-85.3] 0.344
Age, years ≤65/>65 69 (29.1)/168(70.9) 32 (34.0)/62 (66.0) 0.427
Sex, M/F 168 (70.9)/69 (29.1) 60 (63.2)/35 (36.8) 0.215
ECOG PS (%) 0-1/≥2 198 (90.0)/22 (10.0) 75 (83.3)/15 (16.7) 0.147
Stage, Rai III/IV or Binet C no/yes 165 (78.6)/45 (21.4) - -
Bulky lymph nodes (> 5cm) no/yes 20 (8.9)/204 (91.1) - -
Comorbidities  0-1/≥2 98 (41.7)/137 (58.3) - -
Creatinine clearance (mL/min) ≤ 70/>70 100 (46.9)/113 (53.1) - -
CD38 (>20%) neg/pos 52 (47.3)/58 (52.7) - -
17p- yes/no 23 (12.6)/ 160 (87.4) 33 (39.8)/ 50 (60.2) <0.001
FISH 13q-/+12/11q-/17p-/no aberrations 45 (24.6)/32 (17.5)/38 (20.8)/23 (12.6)/45 (24.6) - -
IGHV Mutated/unmutated 40 (27.4)/106 (72.6) 14 (38.9)/22 (61.1) 0.251
Months between 1st and 2nd treatment <36/≥ 36 124 (52.3)/113 (47.7) 54 (75.0)/18 (25.0) 0.001
Previous treatment -
ORR rate to 1st line treatment (%) yes/no 195 (82.3)/42 (17.7) 56 (78.9)/15 (21.1) 0.636
Refractory no/yes 174 (90.6)/18 (9.4) - -
CIT no/yes 95 (41.0)/137 (59.0) 22 (23.7)/71 (76.3) 0.005
Chemo Chl/FL-based/bendamustine 39 (41.1)/42 (44.2)/14 (14.7) - -
CIT Chl/F-based/bendamustine 19 (13.9)/77 (56.2)/41 (29.9) - -
<6 cycles and/or dose reductions yes/no 140 (59.6)/95 (40.4) - -
n: number; ECOG: Eastern Cooperative Oncology Group; neg: negative; pos: positive; ORR: overall response rates; chemo: chemotherapy; Chl: chlorambucil; CIT: chemoim-
munotherapy; M: male; F: female; FL: fludarabine.
First-line treatment included CIT regimens combining
rituximab with fludarabine (with or without cyclophos-
phamide), bendamustine or chlorambucil in 59% of
patients; 41% of patients received chemotherapy or, in 2
cases, single agent treatment with rituximab or alem-
tuzumab. No patient received ibrutinib or other novel oral
agents front line. The use of chemotherapy alone front
line was more frequent before 2010 (52.8% of patients)
than from 2011 onwards (27.9% of patients). Eighteen
patients (9.4%) were refractory to first-line treatment.
Treatment with BR
One hundred and sixty-five of the 237 patients (69.6%)
received the planned number of cycles; treatment was dis-
continued early in 72 patients as a result of toxicity (n=39),
withdrawal of consent (n=7), progressive disease (n=6), or
for other reasons (n=20). The number of cycles actually
administered to patients who discontinued treatment was
≥4 in 52.8% (n=38) of cases. 
Dose reduction of over 10% of the planned dose of ben-
damustine (i.e. <70 mg/m2) was recorded in 28.9% of
cases; a treatment delay occurred in 22.5% of patients.
Overall, 95 patients (40.1%) received 6 cycles without
dose reduction. The median dose administered to the
patients who discontinued treatment or received a
reduced dose was 350 mg/m2.
Efficacy 
The 12-month PFS rate was 78.6% (95%CI: 73.5-
84.1%). The estimated PFS at 30 and 60 months was
30.9% (95%CI: 24.8-38.5%) and 16.2% (95%CI: 10.6-
24.6%), respectively, with a median overall PFS of 25
months (Figure 1) (median follow up 37.1 months, range
0.4-98.5). 
Factors predicting for a shorter PFS at univariate analysis
(Table 2) were 17p deletion (median 14.5 months vs. 25.5
months), U-IGHV (median 20.7 months vs. 32.1) and a less
than 36-month interval between first- and second-line
treatment (median 21.1 months vs. 26.8), whereas an
advanced stage was of borderline significance (median
20.6 vs. 25.8 months). Age (cutoff 65 years), creatinine
clearance [cutoff 70 mL/minute (min)] and the presence or
absence of 2 or more comorbidities had no impact on PFS.
The presence of 17p-, U-IGHV and Binet/Rai stage C/III-
IV were associated with a shorter PFS at multivariate
analysis (Table 2). Patients with a low-risk profile, i.e.
without del(17p), with M-IGHV and Rai stage 0-2 (12.2%
of the total patient population), had a median PFS of 40.4
months compared to 20.7 months in the remaining
patients (P=0.003) (Online Supplementary Figure S1). 
The ORR was 82.3% and the probability of attaining a
response was significantly lower in patients with del(17p)
(69.6%) compared to patients with del(11q) (73.7%),
del(13q) (82.2%), no aberrations (86.7%) or +12 (96.9%)
(P=0.04). The other clinico-biological variables had no sig-
nificant impact on the ORR (Online Supplementary Table
S2).
The TTNT at 12 months was 18.1% (95%CI: 12.6-22.2)
(median 31.3 months) (Online Supplementary Figure S2). A
shorter TTNT was associated with del(17p) (median 20.2
months vs. 34.6) and with the group of patients who
received previous CIT vs. chemotherapy as front-line reg-
imen (27.2 months vs. 40.4) (Table 3). An U-IGHV status
(29.3 months vs. 45.7) and the presence of 2 or more
A. Cuneo et al.
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Figure 1. Progression-free survival (PFS) of patients treated with bendamustine and rituximab (BR) second-line. PFS of all 237 patients (A), by fluorescence in situ
hybridization (B), IGHV status (C), and interval between first-line and second-line treatments (D).
A B
C D
comorbidities (27.2 months vs. 39.1) were of borderline
significance, whereas age and the creatinine clearance had
no impact on TTNT. First-line treatment with a CIT regi-
men was the only predictive factor for a shorter TTNT at
multivariate analysis.
Seventy-three patients died due to CLL (n=14), infection
with or without active CLL (n=27), second primary
tumors (n=7), Richter’s syndrome (n=4). In 12 patients, the
cause of death was not reported. Other causes of death in
single patients (n=9) are listed in Online Supplementary
Table S3.
Overall survival at 12, 36 and 60 months was 92.7%,
72.2% and 54%, respectively, with a median OS of 74.5
months (Figure 2). Fifty-eight percent of patients in
advanced stage were alive at 36 months compared to
75.8% in stage 0-II; 42.4% of patients who did not
respond to BR were alive at 36 months compared to
78.2% of those who responded. An advanced stage (i.e.
Rai stage III-IV or Binet stage C) and resistant disease were
the only parameters significantly associated with a shorter
OS at univariate and multivariate analysis (Table 4 and
Figure 2).
Safety 
A detailed report of grade 3-5 adverse events (AE) is
shown in Online Supplementary Table S4. Thirty-three per-
cent of patients (n=79) reported at least one grade 3-4 AE.
Overall, cytopenia was recorded in 24.9% of patients.
Grade 3-4 neutropenia (including febrile neutropenia)
occurred in 20.7% of cases, thrombocytopenia in 6
patients (2.5%), anemia in 3 patients (1.2%), 2 of whom
had autoimmune hemolytic anemia. Grade 3-5 infections
were recorded in 16 patients including 4 with febrile neu-
tropenia (6.7%), 8 of whom (3.4%) had a lung infection.
One case of fatal infection was reported (encephalitis).
Rash and/or dermatitis were reported in 2 patients (0.8%).
Efficacy of ibrutinib in the UK CLL forum and in the
Italian Named Patient Program
Ninety-five patients were treated in 2014-2015 with sin-
gle agent ibrutinib in second-line within the NPP (73 in the
UK and 22 in Italy). Median follow up in the UK cohort
was 3.1 years. These 95 patients were heterogeneous in
baseline risk factors (Table 1), with an Eastern
Cooperative Oncology Group (ECOG) PS≥2 being the
Efficacy of BR as first salvage treatment in CLL
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Table 2. Progression-free survival (PFS) with bendamustine and rituximab (BR) in second-line: univariate and multivariate analysis.
Univariate Multivariate
Variable HR (95% CI) P HR (95% CI) P
Age, years ≤65 vs. >65 0.899 (0.636-1.271) 0.5467 - -
Sex, F vs.M 1.110 (0.787-1.566) 0.5519 - -
Stage others vs. Rai III/IV or Binet C 0.676 (0.454-1.005) 0.0529 0.536 (0.319-0.903) 0.0192
Bulky lymph nodes (>5cm) yes vs. no 1.643 (0.959-2.815) 0.0705 - -
Comorbidities 0-1 vs. ≥2 1.159 (0.844-1.592) 0.3625 - -
Creatinine clearance (mL/min) ≤70 vs. > 70 1.179 (0.846-1.643) 0.3312 - -
CD38 (>20%) neg vs. pos 0.841 (0.531-1.330) 0.4587 - -
FISH 17p- vs. others 1.965 (1.214-3.180) 0.0060 2.92 (1.61-5.296) 0.0004
IGHV mutated vs. unmutated 0.484 (0.297-0.787) 0.0035 0.53 (0.299-)0.94 0.0299
Months between 1st and 2nd treatment < 36 vs. ≥36 1.398 (1.018-1.921) 0.0387 - -
First-line chemo vs. CIT 0.846 (0.612-1.168) 0.3088 - -
<6 cycles and/or dose reductions no vs. yes 0.752 (0.547-1.034) 0.0794 - -
HR: Hazard Ratio; CI: Confidence Interval; Chemo: chemotherapy; CIT: chemoimmunotherapy; F: female; M: male.
Table 3. Time to next anti-leukemic treatment with bendamustine and rituximab second-line: univariate and multivariate analysis.
Univariate Multivariate
Variable HR (95% CI) P HR (95% CI) P
Age (years) ≤65 vs. >65 1.299 (0.918-1.838) 0.1400 - -
Sex, F vs.M 1.040 (0.716-1.511) 0.8349 - -
Stage others vs. Rai III/IV or Binet C 0.881 (0.557-1.393) 0.5873 - -
Bulky lymph nodes (>5 cm) yes vs. no 1.598 (0.877-2.912) 0.1256 - -
Comorbidities 0-1 vs. ≥2 1.372 (0.978-1.923) 0.0671 - -
Creatinine clearance (mL/min) ≤ 70 vs. > 70 0.833 (0.579-1.199) 0.3261 - -
CD38 (>20%) neg vs. pos 1.079 (0.650-1.793) 0.7678 - -
FISH 17p- vs. others 1.863 (1.096-3.166) 0.0215 - -
IGHV mutated vs. unmutated 0.597 (0.345-1.033) 0.0653 - -
Months between 1st and 2nd treatment < 36 vs. ≥36 1.044 (0.741-1.469) 0.8062 - -
First-line chemo vs. CIT 0.586 (0.407-0.843) 0.0040 0.59 (0.41-0.84) 0.0040
<6 cycles and/or dose reductions no vs. yes 0.776 (0.546-1.104) 0.1593 - -
HR: Hazard Ratio; CI: Confidence Interval; Chemo: chemotherapy; CIT: chemoimmunotherapy; F: female; M: male.
only predictive factor with borderline statistical signifi-
cance of shorter survival (Online Supplementary Table S5).
When restricting the analysis to patients who had received
CIT front-line (Table 5), the ibrutinib cohort and the BR
cohort were comparable in terms of median age, ECOG
PS, ORR rate to first-line treatment, and frequency of U-
IGHV (available in a proportion of cases), although with a
slightly shorter interval between first- and second-line
treatment in the ibrutinib cohort (interval <36 months in
76.1% vs. 59.1% of patients) and a higher number of
patients with 17p deletion in the ibrutinib cohort (36.1%
vs. 14.8%). When excluding patients with del(17p) from
the analysis, there was no significant difference in OS
between the 39 patients treated with ibrutinib (63% alive
at 36 months, 95%CI: 48.8-81.6) and the 92 patients treat-
ed with BR (74.4% alive at 36 months, 95%CI: 64.7-85.5
(Figure 3). A subanalysis of the OS in patients with intact
17p and with a less than 36-month interval between first-
line and first salvage treatment in the BR cohort (n=55)
and in the ibrutinib cohort (n=33) showed no significant
difference, with 72.6% of patients alive at three years
with BR (95%CI: 60.1-87.7) and 59.8% alive at three years
with ibrutinib (95%CI: 44.2-80.7) (P=0.19).
Discussion
Accepting the limitations of retrospective analyses, we
set out to collect data on the efficacy of BR, one of the
most widely utilized CIT regimens in CLL. We elected to
include in this study only patients who received second-
line treatment with BR given the limited availability of
published data in this setting in order to contribute new
information that may assist clinicians in the selection of
the most appropriate first salvage treatment in CLL. To
minimize possible selection biases and imprecise report-
ing of data: i) we encouraged clinicians to report all
patients who initiated BR treatment; ii) we analyzed the
reported data according to the intention-to-treat principle;
and iii) we performed computerized and manual consis-
tency checks on each case report form.
Besides PFS, we included objective efficacy measures of
the BR regimen, such as OS and the TTNT. Keeping in
mind that response assessment may vary among centers
and that bone biopsy was not routinely performed, we
agreed to record as “response” what each treating clinician
graded as “partial” or “complete” remission.
The patient population who received BR included in
this study closely resembled  the typical CLL patient seen
in daily clinical practice in terms of age, PS and comorbidi-
ties.14 The number of patients who completed the planned
treatment (69.6%) was in line with a previous prospective
phase-II GIMEMA study, where 76% of R/R CLL patients
completed treatment.16 This finding suggests that there
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Figure 2. Overall survival (OS)  of patients treated with bendamustine and rituximab
(BR)  second-line. OS  of all 237 patients (A), by stage (B) and by response to BR (C). 
Figure 3. Indirect comparison of overall survival in 39 patients treated second-
line with ibrutinib and in 92 patients treated with bendamustine and rituximab
(Benda+RTX). All patients had intact 17p and received chemoimmunotherapy
as front-line therapy. 
A B
C
P=0.146
Months from treatment start
was minimal, if any, patient selection bias in our study.
The number of grade 3-4 infections (6.7%) is similar to the
4.2% incidence of severe infections in a trial using ben-
damustine and ofatumumab in patients who had received
1-2 previous lines of treatment.16 In another trial using the
BR regimen, the incidence of grade 3 infections was
12.8% in patients who had received 1-5 previous lines of
treatment.15 Thus, our data show that BR is a relatively
safe second-line regimen in terms of infectious complica-
tions in a real-life population. The lower incidence of
grade 3-4 cytopenias in this study compared to other
prospective studies showing a 50-78% incidence of grade
3-4 cytopenias15,16 reflects the policy not to perform a
blood count in the routine practice at the nadir time point
at many centers.
With a 78.6% PFS rate at 12 months (median 25
months), a 31.3-month median TTNT, and a 92.7% OS
rate at 12 months (median 74.5 months), our data show
that the BR regimen is an effective first salvage regimen.
Interestingly, the efficacy of this regimen in terms of PFS,
TTNT and OS was not influenced significantly by age,
creatinine clearance, by the presence of 2 or more comor-
bidities. PFS was negatively influenced by advanced stage,
del(17p) and U-IGHV, confirming the strong prognostic
significance of these parameters24 also in the second-line
setting. Patients without any of these unfavorable charac-
teristics experienced a prolonged median PFS (40.4
months).
Although PFS estimation should be interpreted with
caution in a retrospective analysis, our data are similar to
those observed in a prospective phase II GIMEMA trial16
that reported a median PFS of 23.6 months with ben-
damustine and ofatumumab in 49 R/R CLL (61% with 1
previous treatment, 39% with 2 previous lines). In another
analysis of BR in patient who had received a median num-
ber of 2 previous treatments (range 1-5), the median PFS
was 15.2 months (95%CI: 12.5-17.9 months).15 A 18-
month median PFS was reported with BR as first salvage
after fludarabine, cyclophosphamide and rituximab in 62
patients.13
Time to next treatment was longer in those patients
who had received chemotherapy as first-line treatment. It
is worth noting that even though published guidelines
proposed the preferential usage of CIT, 27.9% of our
patients who started treatment after 2010 had received
only chemotherapy as initial treatment. 
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Table 4. Overall survival after univariate and multivariate analysis.
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age, years ≤65 vs. >65 0.741 (0.439-1.250) 0.2612 - -
Sex, M vs. F 0.836 (0.491-1.425) 0.5107 - -
Stage, others vs. Rai III/IV or Binet C 0.501 (0.296-0.846) 0.0098 0.547 (0.320-0.935) 0.0276
Bulky lymph nodes (>5 cm) yes vs. no 1.161 (0.464-2.905) 0.7492 - -
Comorbidities 0-1 vs. ≥2 1.069 (0.671-1.702) 0.7797 - -
Creatinine clearance (mL/min) ≤70 vs. >70 1.401 (0.850-2.308) 0.1855 - -
CD38 (>20%) neg vs. pos 0.722 (0.356-1.465) 0.3665 - -
FISH 17p- vs. others 1.500 (0.734-3.064) 0.2663 - -
IGHV mutated vs. unmutated 0.604 (0.290-1.254) 0.1761 - -
Months between 1st and 2nd treatment <36 vs. ≥36 1.496 (0.934-2.398) 0.0941 - -
First-line chemo vs. CIT 0.977 (0.609-1.565) 0.9216 - -
<6 cycles and/or dose reductions no vs. yes 0.706 (0.444-1.123) 0.1419 - -
ORR CR; Cri; PR; nPR/vs. PD; SD; NR 0.330 8 (0.197-0.552) <.0001 0.344 (0.198-0.595) 0.0001
HR: Hazard Ratios; CI: Confidence Interval; Chemo: chemotherapy; CIT: chemoimmunotherapy; ORR: overall response rate; CR: complete remission with incomplete marrow
recovery; nPR: nodular partial response; F: female; M: male; NR: no remission; PD: progressive disease; PR: partial remission; SD: stable disease. 
Table 5. Baseline characteristics of patients treated with chemoimmunotherapy in first-line in the bendamustine and rituximab (BR) and in the
ibrutinib cohorts (UK + NPP GIMEMA).
Variable BR (n=137) Ibrutinib (n=71) P
Median age, years (range) 68.2 (39.4-84.6) 67.1 (27.5-85.3) 0.603
Age, years (%) ≤65/>65 39 (34.5)/74 (65.5) 27 (38.6)/43 (61.4) 0.691
Sex, (%) M/F 91 (66.4)/46 (33.6) 45 (63.4)/ 26 (36.6) 0.777
ECOG PS (%) 0-1/≥2 113 (91.9)/10 (8.1) 57 (82.6)/ 12 (17.4) 0.090
Months between 1st line and 2nd line 
Median (range) 30.60 (0.40, 79.40) 19.40 (1.80, 77.60) 0.001
n. <36/≥36 (%) 81 (59.1)/56 (40.9) 54 (76.1)/17 (23.9) 0.023
Response to 1st line treatment (%) no/yes 28 (20.4)/109 (79.6) 8 (15.1)/45 (84.9) 0.524
IGHV (%) mutated/unmutated 17 (19.5)/70 (80.5) 8 (32.0)/17 (68.0) 0.295
17p- (%) yes/no 16 (14.8)/92 (85.2) 22 (36.1)/39 (63.9) 0.003
NPP GIMEMA: Named Patient Program-Gruppo Italiano Malattie Ematologiche dell'Adulto; ECOG: Eastern Cooperative Oncology Group; n: number. F: female; M: male; PS: per-
formance status. 
The survival data in our analysis (92.7% alive at 12
months and 72.2% at 36 months) reflect previous experi-
ences with bendamustine and anti-CD20 in clinical tri-
als,16,25 showing that this combination is equally effective
in clinical practice across many centers. Negative predic-
tive factors on OS were represented by advanced stage
and chemorefractory disease, whereas the presence of
del(17p) was not associated in our analysis with a signifi-
cantly shorter OS, possibly due to the relatively low num-
ber of patients (n=23) and to the use of effective salvage
regimens in subsequent lines of treatment. Accordingly,
the survival in the BR arm of the Helios trial after adjusting
for crossover to BR and ibrutinib was close to 90% at 12
months and more than 80% at 24 months.26
Thus, the data presented here show that BR is an effica-
cious first salvage regimen in CLL in a real-life population,
including elderly patients, patients with 2 or more comor-
bidities and a creatinine clearance less than 70 mL/min.
The outcome was better in patients with favorable genetic
features and with early/intermediate disease stage.
Importantly, no significant differences in terms of OS
were noted in this real-life report with respect to the sur-
vival data recently observed in clinical trials.
Because no direct comparison was performed between
CIT and new oral agents in first relapse, we elected to
compare our data with ibrutinib used in a real-life patient
population treated in the UK and in Italy using OS as an
objective end point. We restricted our comparative analy-
sis to patients who had previously received CIT because
this is the recommended initial treatment in CLL. The BR
and ibrutinib cohorts had similar baseline risk factors and,
when excluding patients with del(17p) from the analysis
as nowadays they would no longer be exposed to second-
line CIT, there was no difference in  OS (Figure 3).
Interestingly, no difference in OS was found with BR or
ibrutinib when including in the subanalysis patients with
a less than 36-month interval between front-line and first
salvage treatment. The survival curve showed an excess of
early deaths in the ibrutinib cohort compared to the BR
cohort. Due to the small size of the patient population
included in this analysis, there is no recurrent pattern or
obvious explanation for this observation; severe infection
and Richter’s syndrome in 2 patients each were the only
recurrent causes of death in the first 12 months. It remains
unclear as to whether ibrutinib directly contributed to any
of these deaths.
The observed outcome for ibrutinib-treated patients in
this observational study could be due to premature inter-
ruption of ibrutinib exposure. It is noteworthy that in the
UK and Ireland data on the overall cohort of R/R CLL
treated with ibrutinib, discontinuations during the first
year were due to AEs (54%), Richter’s transformation
(26%), and progressive CLL (17%). Beyond the first year,
the rate of discontinuations due to progressive CLL
increased to 29%.27
When comparing CIT and novel inhibitors, one also has
to consider the long-term detrimental effects due to the
clonal selection and DNA damage occurring with repeti-
tive lines of chemotherapy-based treatments, resulting in
second tumors, acute leukemias/myelodysplastic syn-
dromes, that cannot be evaluated in the short follow up of
our retrospective study. On the other hand, elegant in vitro
studies have shown that treatment of mouse B cells with
idelalisib or duvelisib, and to a lesser extent ibrutinib,
increased somatic hypermutation through enhanced
expression of activation-induced cytidine deaminase.28
In another analysis including R/R CLL in second and
subsequent lines of treatment,29 an OS advantage was
noted when comparing ibrutinib (with or without BR) and
BR alone.30 In other studies arriving at the same conclu-
sion,31,32 chemotherapy +/- anti CD20 regimens used in a
real-world setting were compared with ibrutinib data of
the clinical trials Resonate and Helios. However, there is
now evidence that adherence to treatment with ibrutinib
in the real-world population did not reflect the data
obtained in clinical trials,22,33 possibly due to the hetero-
geneity of the patient populations or to a more limited
experience of physicians in managing side effects occur-
ring on treatment. Furthermore, the UK real-life data show
that duration of ibrutinib therapy and OS seem very sim-
ilar when ibrutinib is used at first or subsequent relapses,
suggesting that the relative benefit for ibrutinib compared
with chemotherapy is more evident in patients with mul-
tiple relapse where re-treatment with further chemother-
apy results in progressively worse response rates and
remission duration. It is noteworthy that a highly signifi-
cant PFS advantage with the BCL2 inhibitor venetoclax
plus rituximab compared to BR has been recently reported
in the planned interim analysis of the randomized phase
III Murano study, where 42.8% of patients had received 2
or more lines of therapy.34 However, in this trial, an OS
benefit has not yet been shown according to the prede-
fined statistical model.
Although, obviously, data derived from different series
must be treated with caution, these data suggest that BR
and ibrutinib may be equally effective in terms of OS
when used as first salvage treatment in CLL patients with-
out 17p deletion managed in the real-life setting. Whether
this is due to limited compliance of patients and/or subop-
timal management of side effects with the novel therapies
remains to be established.
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